Keros Therapeutics (KROS) EBITDA (2019 - 2026)
Keros Therapeutics (KROS) EBITDA from Mar 31, 2019 to Mar 31, 2026. The TTM Keros Therapeutics (KROS) EBITDA is -$109M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Keros Therapeutics (KROS) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +1105.88% |
| 3 Years TTM | -5.48% |
| 5 Years TTM | +16.07% |
| All Time TTM | +34.99% |
Annual EBITDA change of Keros Therapeutics (KROS)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$25M | -136.87% |
| 2025 | $69M | -132.96% |
| 2024 | -$210M | +23.93% |
| 2023 | -$169M | +48.20% |
| 2022 | -$114M | +103.82% |
| 2021 | -$56M | +20.72% |
| 2020 | -$46M | +348.12% |
| 2019 | -$10M | N/A |
Comparison Keros Therapeutics (KROS) five years EBITDA CAGR with competitors
Keros Therapeutics (KROS) five years EBITDA CAGR is 16.07%.